In a treatment setting a drug test result is clinical information, not a verdict. ToxiPharm helps opioid treatment programs and addiction treatment centers design monitoring that informs care decisions and train staff to interpret what comes back.
Drawn from day-to-day practice in opioid treatment settings, where the same handful of questions account for most of the confusion.
A buprenorphine positive alone does not confirm the patient is taking it as prescribed. The norbuprenorphine to buprenorphine ratio distinguishes genuine dosing from drug added directly to the specimen, and low-dose formulations may not be detectable at all.
Dilute and abnormal results get treated as evidence of tampering when low muscle mass, renal disease, diabetes, storage conditions, and urinary tract infection all produce abnormal validity markers in patients who did nothing wrong.
Medetomidine, xylazine, nitazenes, and designer benzodiazepines are not on standard panels. A negative screen in a patient with obvious sedation or an atypical withdrawal course is a testing limitation, not a clinical contradiction.
Quetiapine on a methadone screen, bupropion or trazodone on an amphetamine screen, venlafaxine on PCP. Patients on psychiatric medications generate unexpected positives that can damage therapeutic trust when acted on without confirmation.
Testing frequency, panel design, confirmation criteria, and written policy, aligned with ASAM and SAMHSA guidance and with how results will actually be used in treatment decisions.
Training for counselors, nurses, and prescribers on interpreting results, MOUD monitoring, specimen validity, and recognizing what current panels miss.
Direct consultation on individual results that do not make sense, including adherence questions, unexpected positives, and results that conflict with the clinical picture.
Already built and free to use, including materials you can print and hand to patients.
Check whether a prescribed medication explains a positive, look up detection windows, or work through a cannabis excretion series.
Open the tools →Printable alerts on medetomidine, nitazenes, and cychlorphine written for patients, including naloxone guidance and wallet cards.
View patient alerts →If your protocol was inherited rather than designed, or your staff are interpreting results without training, a review is usually the highest-yield place to start.
The clinical toxicology newsletter: drug trends, regulatory updates, and practice-relevant science, delivered free.
No spam. Unsubscribe anytime.